# US 2010/0166855 A1 · Oral insulin composition and methods of making and using thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0166855 A1
- Document ID: US20100166855A1
- Status: Published application
- Kind: A1
- Application number: 12/719,633
- Filed: 2010-03-08
- Published: 2010-07-01
- Earliest claimed: 2003-03-04
- Inventors: Vladimir SABETSKY
- Web page: https://patentgrep.com/patent/US20100166855A1

## CPC

- A61K 9/0095: {Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches (A61K9/0007 takes precedence; eatable gels or foams A61K9/0056; oral mucosa adhesive forms A61K9/006)}
- A61K 9/1652: {Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin (homeopathic globules A61K9/1623)}
- A61K 38/28: Insulins
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 5/48: of the pancreatic hormones
- A61P 5/50: for increasing or potentiating the activity of insulin
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K 9/107: Emulsions {; Emulsion preconcentrates; Micelles (composition of emulsions A61K47/00)}
- A61K 9/1676: {having a drug-free core with discrete complete coating layer containing drug (adsorbates of liquid drug formulations on inert powders without simultaneous granulation step A61K9/141; with further drug-free outer coating A61K9/5078; drug conjugated to non-active particles A61K47/6921)}
- A61K 47/36: Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A method of lowering blood glucose in a mammal includes orally administering a therapeutically effective amount of crystallized dextran microparticles and insulin to the mammal to lower blood glucose of the mammal. The composition may be a one phase or a structured multi-phase composition for controlled release of insulin.

## Claims

### Claim 1

A method of preparing a composition for controlled release of a therapeutic agent, comprising:
providing an aqueous solution of dextran with a molecular weight of 1.0 to 200 kDa, wherein the dextran is at a concentration of 40-65% by weight of said aqueous solution;
forming a dextran matrix from the aqueous solution at a temperature ranging from 20-90° C.; and
adding a therapeutic agent to at least a portion of the dextran matrix, thereby producing a dextran matrix with the therapeutic agent.

### Claim 2 (depends on 1)

The method of claim 1, wherein the molecular weight of the dextran is 20 to 75 kDa

### Claim 3 (depends on 1)

The method of claim 1, wherein the dextran is present in said solution at a concentration of 55-65% by weight.

### Claim 4 (depends on 1)

The method of claim 1, wherein water is eliminated from at least a portion of the matrix by drying.

### Claim 5 (depends on 4)

The method of claim 4, wherein said drying is performed at a temperature ranging from 20-90° C.

### Claim 6 (depends on 1)

The method of claim 1, wherein the therapeutic agent is dissolved in the aqueous solution.

### Claim 7 (depends on 1)

The method of claim 1, wherein the therapeutic agent is added at a concentration of 15-30% by weight in the aqueous solution.

### Claim 8 (depends on 1)

The method of claim 1, wherein the therapeutic agent is insulin.

### Claim 9 (depends on 1)

A pharmaceutical composition comprising a dextran matrix prepared by the process of claim 1.

### Claim 10 (depends on 9)

The pharmaceutical composition of claim 9, wherein the composition is a tablet or capsule.

### Claim 11 (depends on 9)

The pharmaceutical composition of claim 9, wherein the therapeutic agent is insulin.

### Claim 12 (depends on 9)

The pharmaceutical composition of claim 9, wherein the therapeutic agent is insulin and the composition is a tablet or capsule.
